Skip to main content

Rydym wedi cadw rhai ffeiliau o'r enw cwcis ar eich dyfais. Y cwcis hyn yw:

  • Hanfodol ar gyfer y safle i weithio
  • Helpu i wella ein gwefan drwy gasglu ac adrodd gwybodaeth am sut rydych chi'n ei defnyddio

Hoffem hefyd arbed rhai cwcis i helpu i deilwra cyfathrebu.

BETA
Rydych yn edrych ar fersiwn wedi'i ddiweddaru o'r gwasanaeth hwn - bydd eich adborth yn ein helpu i'w wella.

VEAT

Consultancy Services relating to the design, validation and Qualification of Clean Rooms within Gene Therapy Innovation Manufacturing Centre

  • Cyhoeddwyd gyntaf: 26 Ionawr 2022
  • Wedi'i addasu ddiwethaf: 26 Ionawr 2022

Nid yw'r prynwr yn defnyddio'r wefan hon i weinyddu'r hysbysiad.

I gofnodi eich diddordeb neu gael gwybodaeth neu ddogfennau ychwanegol, darllenwch y cyfarwyddiadau yn Nhestun Llawn yr Hysbysiad. (NODER: Nid oes angen ymateb i Hysbysiadau Dyfarnu Contractau a Hysbysiadau Gwybodaeth Ymlaen Llaw fel arfer)

Cynnwys

Crynodeb

OCID:
Cyhoeddwyd gan:
University of Sheffield
ID Awudurdod:
AA20643
Dyddiad cyhoeddi:
26 Ionawr 2022
Dyddiad Cau:
-
Math o hysbysiad:
VEAT
Mae ganddo ddogfennau:
Nac Ydi
Wedi SPD:
Nac Ydi
Mae ganddo gynllun lleihau carbon:
AMH

Crynodeb

Services are required for a number of tasks during the Qualification and Validation stages of the build completion of the Research and Development facilities including all Quality Control, Clean Room areas in grades C and grade D environments in addition to all process areas across the site and supporting site operations such as major infrastructure and support services such as logistics in addition to other areas.

These works are to cover the following areas / requirements:

Qualification Requirement Matrix prepared to track Validation Lifecycle and to support;

MHRA Audit. Used on previous MHRA audits and proved effective;

Validation Assessment, User Requirement Specifications, Validation Plan, Design Document Reviews;

Vendor Document Reviews, Factory Acceptance Tests Site Acceptance Tests (Commissioning);

COTS Installation/Operational Qualification Protocol, Installation Qualification Protocol;

Thermal Mapping Protocol (Empty and Loaded), Operational Qualification Protocol;

Performance Qualification Protocol, Validation Summary Reports.

It is envisaged that the majority of documentation preparation will be carried out remotely from the new build site however close working relationships will be required with attendance at site meetings for all aspects of the build and clean room fit outs will be required therefore an estimate of 50% site attendance is anticipated.

It will be a requirement that the provider will regularly visit the site throughout the construction period to ensure that the build is being documented to a suitable standard to allow for information leveraging into qualification. These visits will also be to ensure that the MHRA are suitably informed throughout all stages of the construction period.

Attendance by the provider and being that professional capacity for all engagement with the MHRA will be a major requirement and throughout the Licence application process and to assist the client in this application process through to successfully licence being granted.

Major recent experience is therefore a pre-request in interaction with the MHRA in the field of both Cell and Gene Therapy, Clean Room Manufacturing, Covid-19 Vaccine Response and recent demonstrated deployment / experience within Cell and Gene Therapy is of the highest importance.

As part of the process of validation and qualification, down stream training will be required to be delivered to allow for periodic validation of clean room areas by incumbent UoS GTIMC and UoS Estates and Facilities staff.

The project has extremely aggressive timelines with build construction due for completion in July 2022 and therefore standing up of this service will be required to be in place during the early stages of February 2022.

Testun llawn y rhybydd

Hysbysiad tryloywder gwirfoddol ymlaen llaw

Adran I: Endid contractio

I.1) Enw a chyfeiriad

UNIVERSITY OF SHEFFIELD

Western Bank

SHEFFIELD

S102TN

UK

Person cyswllt: Jamie Shaw

Ffôn: +44 1142221516

E-bost: jamie.shaw@sheffield.ac.uk

NUTS: UKE32

Cyfeiriad(au) rhyngrwyd

Prif gyfeiriad: www.sheffield.ac.uk

I.4) Y math o awdurdod contractio

Corff a lywodraethir gan gyfraith gyhoeddus

I.5) Prif weithgaredd

Addysg

Adran II: Gwrthrych

II.1) Cwmpas y caffaeliad

II.1.1) Teitl

Consultancy Services relating to the design, validation and Qualification of Clean Rooms within Gene Therapy Innovation Manufacturing Centre

II.1.2) Prif god CPV

71530000

 

II.1.3) Y math o gontract

Gwasanaethau

II.1.4) Disgrifiad byr

The University of Sheffield (UoS) is establishing a new 'Gene Therapy Innovation Manufacturing Centre' (GTIMC) to advance scientific discoveries into life-changing treatments for patients with life threatening diseases. The Sheffield GTIMC will be one of three cutting edge hubs in the UK dedicated to advancing the clinical development of new genetic treatments. This facility is due to open in the Summer of 2022 and further details can be found at the following link:-

https://www.sheffield.ac.uk/news/new-gene-therapy-innovation-centre-advance-scientific-discoveries-life-changing-treatments

The services to be procured under this VEAT include the Qualification and Validation stages of the build completion of the Research and Development facilities including all Quality Control, Clean Room areas in grades C and grade D environments including obtaining full MHRA Licence.

II.1.6) Gwybodaeth am lotiau

Mae’r contract hwn wedi’i rannu’n lotiau: Na

II.1.7) Cyfanswm gwerth y caffaeliad

Gwerth heb gynnwys TAW: 370 000.00 GBP

II.2) Disgrifiad

II.2.3) Man cyflawni

Cod NUTS:

UKE32


Prif safle neu fan cyflawni:

Gene Therapy Innovation and Manufacturing Centre, Faculty of Medicine Dentistry of Health, The University of Sheffield

II.2.4) Disgrifiad o’r caffaeliad

Services are required for a number of tasks during the Qualification and Validation stages of the build completion of the Research and Development facilities including all Quality Control, Clean Room areas in grades C and grade D environments in addition to all process areas across the site and supporting site operations such as major infrastructure and support services such as logistics in addition to other areas.

These works are to cover the following areas / requirements:

Qualification Requirement Matrix prepared to track Validation Lifecycle and to support;

MHRA Audit. Used on previous MHRA audits and proved effective;

Validation Assessment, User Requirement Specifications, Validation Plan, Design Document Reviews;

Vendor Document Reviews, Factory Acceptance Tests Site Acceptance Tests (Commissioning);

COTS Installation/Operational Qualification Protocol, Installation Qualification Protocol;

Thermal Mapping Protocol (Empty and Loaded), Operational Qualification Protocol;

Performance Qualification Protocol, Validation Summary Reports.

It is envisaged that the majority of documentation preparation will be carried out remotely from the new build site however close working relationships will be required with attendance at site meetings for all aspects of the build and clean room fit outs will be required therefore an estimate of 50% site attendance is anticipated.

It will be a requirement that the provider will regularly visit the site throughout the construction period to ensure that the build is being documented to a suitable standard to allow for information leveraging into qualification. These visits will also be to ensure that the MHRA are suitably informed throughout all stages of the construction period.

Attendance by the provider and being that professional capacity for all engagement with the MHRA will be a major requirement and throughout the Licence application process and to assist the client in this application process through to successfully licence being granted.

Major recent experience is therefore a pre-request in interaction with the MHRA in the field of both Cell and Gene Therapy, Clean Room Manufacturing, Covid-19 Vaccine Response and recent demonstrated deployment / experience within Cell and Gene Therapy is of the highest importance.

As part of the process of validation and qualification, down stream training will be required to be delivered to allow for periodic validation of clean room areas by incumbent UoS GTIMC and UoS Estates and Facilities staff.

The project has extremely aggressive timelines with build construction due for completion in July 2022 and therefore standing up of this service will be required to be in place during the early stages of February 2022.

II.2.11) Gwybodaeth am opsiynau

Opsiynau: Na

II.2.13) Gwybodaeth am Gronfeydd yr Undeb Ewropeaidd

Mae'r broses gaffael yn gysylltiedig â phrosiect a/neu raglen a ariennir gan gronfeydd yr Undeb Ewropeaidd: Na

II.2.14) Gwybodaeth ychwanegol

Regulation 32 of PCR 2015 is being applied as in 32. (2) (b) (ii)

No contract will be entered into until after a 10 calendar day period from the submission of the VEAT notice date.

Section IV: Gweithdrefn

IV.1) Disgrifiad

IV.1.1) Y math o weithdrefn

Y weithdrefn a negodwyd heb gyhoeddiad ymlaen llaw

Cyfiawnhau'r weithdrefn ddyfarnu a ddewiswyd:

Dim ond am y rheswm canlynol y gall gweithredwr economaidd penodol ddarparu'r gwaith, y cyflenwadau neu'r gwasanaethau: diffyg cystadleuaeth am resymau technegol

Esboniad:

The University of Sheffield signed an agreement with Cell and Gene Therapy Catapult (CGT Catapult) to tech transfer the Catapult AAV (Adeno-Associated Virus) manufacturing platform to Gene Therapy Innovation and Manufacturing Centre' (GTIMC). This task is one of the milestones under the funding award supporting the establishment of the GTIMC in Sheffield. The milestone must be completed within 12 months of the start of the GTIMC Project, i.e. by end July 2022. Any delay in the tech transfer will also impact on the milestone related to MHRA accreditation of GTIMC due by end Q4 2022.

The GTIMC and University of Sheffield will jointly acquire a technology license from CGT Catapult to be able to use their AAV manufacturing platform. This platform was established and optimised based on the processes developed using the proposed list of equipment.

A single source is therefore proposed to formalise the solution provided by Complete Technical Solutions Ltd for the following reasons: -

Significant recent (within the previous 6 months) experience is therefore a pre-request in interaction with the MHRA in the field of both Cell and Gene Therapy, Clean Room Manufacturing, Covid-19 Vaccine Response and recent demonstrated deployment / experience within Cell and Gene Therapy is of the highest importance.

To increase the U.K. capacity for GMP clinical vector manufacturing using the catapult process to allow for expansion of U.K. skills and training within the GTIMC space and increase partnerships with other academia which will create a fertile ecosystem for innovation and research excellence in this field across academia.

IV.1.8) Gwybodaeth am Gytundeb Caffael y Llywodraeth (GPA)

The procurement is covered by the Government Procurement Agreement: Ydy

Section V: Dyfarnu contract/consesiwn

V.2 Dyfarnu contract/consesiwn

V.2.1) Y dyddiad y daeth y contract i ben/consesiwn

25/01/2022

V.2.2) Gwybodaeth am dendrau

Dyfarnwyd y contract i gr?p o weithredwyr economaidd: Na

V.2.3) Enw a chyfeiriad y contractwr

Complete Technical Solutions Limited

Manchester

UK

NUTS: UKD36

BBaCh yw’r contractwr: Ydy

V.2.4) Gwybodaeth am werth y consesiwn a’r prif delerau cyllido (heb gynnwys TAW)

Cyfanswm gwerth y consesiwn/lot: 370 000.00 GBP

V.2.5) Gwybodaeth am is-gontractio

Section VI: Gwybodaeth ategol

VI.4) Gweithdrefnau adolygu

VI.4.1) Corff adolygu

High Court of England, Wales & Northern Ireland

London

UK

VI.5) Dyddiad anfon yr hysbysiad hwn

25/01/2022

Codio

Categorïau nwyddau

ID Teitl Prif gategori
71530000 Gwasanaethau ymgynghori ar adeiladu Gwasanaethau goruchwylio safleoedd adeiladu

Lleoliadau Dosbarthu

ID Disgrifiad
100 DU - I gyd

Cyfyngiadau Rhanbarthol ar y Rhybuddion

Mae’r prynwr wedi cyfyngu’r rhybuddion ar gyfer yr hysbysiad hwn i gyflenwyr yn y rhanbarthau canlynol.

ID Disgrifiad
Nid oes cyfyngiadau ar y rhybuddion ar gyfer yr hysbysiad hwn.

Ynglŷn â'r prynwr

Prif gyswllt:
jamie.shaw@sheffield.ac.uk
Cyswllt gweinyddol:
N/a
Cyswllt technegol:
N/a
Cyswllt arall:
N/a

Gwybodaeth bellach

Dyddiad Manylion
Nid oes unrhyw wybodaeth bellach wedi'i lanlwytho.

0800 222 9004

Mae'r llinellau ar agor rhwng 8:30am a 5pm o ddydd Llun i ddydd Gwener.

Rydym yn croesawu galwadau'n Gymraeg.

We welcome calls in Welsh.